ABVC ABVC BIOPHARMA, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1173313 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY234.3%
TTM net income YoY62.5%
TTM EPS YoY76.7%
Revenue 3-yr CAGR12.7%
Net income 3-yr CAGR—
Margins
Gross margin99.9%
Operating margin-850.7%
Net margin-773.6%
FCF margin—
EBITDA margin-840.1%
Returns
ROE-283.6%
ROA-51.4%
ROIC (approx.)-570.9%
Asset turnover0.07x
Leverage & solvency
Liabilities / assets90.4%
Debt / equity0.00x
Current ratio0.33x
Interest coverage-5.25x
Cash quality & payout
Operating cash flow / net income0.41x
Accruals ratio-30.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $296,000 | $509,589 | $152,430 | $969,783 | $355,797 |
| Cost of revenue | — | $763 | $302,037 | $286,415 | $5,086 |
| Gross profit | — | $508,826 | -$149,607 | $683,368 | $350,711 |
| R&D expense | $121,085 | $179,272 | $1.06M | $2.69M | $1.00M |
| SG&A expense | $2.89M | $2.26M | $5.37M | $6.07M | $5.75M |
| Operating income | -$7.15M | -$4.71M | -$6.77M | -$15.11M | -$11.71M |
| Interest expense | $415,890 | $825,899 | $1.31M | $293,968 | $227,210 |
| Pretax income | -$8.35M | -$5.37M | -$8.02M | -$15.51M | -$11.21M |
| Income tax | $24,154 | -$110,539 | $256,006 | $797,778 | $825,024 |
| Net income | -$7.91M | -$4.90M | -$7.79M | -$16.42M | -$12.84M |
| EBITDA | -$7.13M | -$4.67M | -$6.74M | -$15.09M | -$11.69M |
| EPS (basic) | -0.39 | -0.42 | -1.80 | -5.19 | -0.51 |
| EPS (diluted) | -0.39 | -0.42 | -1.80 | -5.19 | -0.51 |
| Weighted avg. shares (diluted) | 20.11M | 11.67M | 4.34M | 3.17M | 25.05M |
| Balance sheet | |||||
| Cash & equivalents | $681,480 | $863,815 | $716,780 | $1.39M | $6.57M |
| Short-term investments | $64,354 | $64,736 | $79,312 | $75,797 | $108,147 |
| Receivables | — | — | $1,530 | $98,325 | $280,692 |
| Inventory | — | — | — | — | $25,975 |
| Current assets | $3.26M | $2.18M | $1.66M | $2.99M | $7.65M |
| PP&E, net | $12.84M | $511,088 | $569,278 | $573,978 | $525,881 |
| Total assets | $21.82M | $7.54M | $7.78M | $9.58M | $13.70M |
| Current liabilities | $6.92M | $6.56M | $6.10M | $5.54M | $3.69M |
| Short-term debt | $755,512 | $840,252 | $899,250 | $1.89M | $1.64M |
| Total liabilities | $8.52M | $6.82M | $6.53M | $6.34M | $4.83M |
| Shareholders' equity | $11.11M | $1.23M | $1.55M | $3.10M | $8.84M |
| Shares outstanding | 25.05M | 13.87M | 7.94M | 3.29M | 24.42M |
| Cash flow statement | |||||
| Operating cash flow | -$2.99M | -$1.81M | -$4.19M | -$7.40M | -$7.60M |
| Capital expenditure | — | — | $21,201 | $119,692 | $17,503 |
| Free cash flow | — | — | -$4.21M | -$7.52M | -$7.62M |
| Investing cash flow | -$1.21M | — | -$360,186 | -$1.72M | -$805,966 |
| Financing cash flow | $4.64M | $1.98M | $3.87M | $4.01M | $10.00M |
| Depreciation & amortization | $25,330 | $32,025 | $28,531 | $23,799 | $11,993 |
| Stock-based compensation | $4.14M | $2.77M | $536,648 | $7.04M | $5.31M |
Free plan shows the latest 5 periods; Pro shows all 19 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.